GuidelineZeitschrift fur Rheumatologie2012
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].
Guideline in Zeitschrift fur Rheumatologie, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- [S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].Zeitschrift fur Rheumatologie · 2018Guideline
- [Recommendations for use of abatacept in patients with rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2014Guideline
- German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Rheumatology international · 2014Guideline
- Perspectives of patients with rheumatoid arthritis towards the use of parenteral methotrexate: a qualitative study.International journal of clinical pharmacy · 2026Article
- Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024.Frontiers in immunology · 2025Review
- Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.Rheumatology and therapy · 2024Article
- [Methotrexate treatment before use of biologics in rheumatoid arthritis : Analysis of guideline compliance].Zeitschrift fur Rheumatologie · 2023Article
- Assessment and Prediction of Adherence to Methotrexate Using Three Self-Report Questionnaires in Patients with Rheumatoid Arthritis.Medicina (Kaunas, Lithuania) · 2023Article
- Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes.Rheumatology and therapy · 2022Article
- Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting.Patient preference and adherence · 2021Article
- [Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].Zeitschrift fur Rheumatologie · 2020Article
- How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy.Journal of clinical medicine · 2019Article
- Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.Rheumatology international · 2018Article
- [In-label treatment of inflammatory joint diseases].Zeitschrift fur Rheumatologie · 2018Review
- [Interpretation of tuberculosis and hepatitis screening before immunosuppressive treatment].Zeitschrift fur Rheumatologie · 2018Article
- [Getting older with rheumatoid arthritis-is there a burnout of the disease?]Zeitschrift fur Rheumatologie · 2018Review
- [Pharmacological treatment of rheumatoid arthritis and its comorbidities].Der Internist · 2018Review
- A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference.Patient preference and adherence · 2018Article
- [How frequent are poor prognostic markers in rheumatoid arthritis? : An estimate based on three epidemiologic cohorts].Zeitschrift fur Rheumatologie · 2017Article
- [The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].Zeitschrift fur Rheumatologie · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following the EULAR recommendations published in 2010 German guidelines for the medical treatment of rheumatoid arthritis were developed based on an update of the systematic literature search and expert consensus. Methotrexate is the standard treatment option at the time of diagnosis, preferably in combination with low dose glucocorticoids. Combined disease-modifying antirheumatic drugs (DMARD) therapy should be considered in patients not responding within 12 weeks. Treatment with biologicals should be initiated in patients with persistent high activity no later than 6 months after conventional treatment and in exceptional situations (e.g. early destruction or unfavorable prognosis) even earlier. If treatment with biologicals remains ineffective, changing to another biological is recommended after 3-6 months. In cases of long-standing remission a controlled reduction of medical treatment can be considered.
Indexed as
Identifiers
22930110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.